A Pooled Analysis of Datopotamab Deruxtecan in Patients With EGFR-Mutated NSCLC
Myung‐Ju Ahn(Sungkyunkwan University), Isamu Okamoto(Kyushu University Hospital), Min Hee Hong(Yonsei University), Paul Howarth(Daiichi Sankyo (United States)), Michael Chargualaf(Daiichi Sankyo (United States)), Yasushi Goto(Tennessee Oncology), Richard W. Joseph(Daiichi Sankyo (United States)), Hidetoshi Hayashi(Nagoya City University), M. Pérol(Centre Léon Bérard), Luis Paz‐Ares(Hospital Universitario 12 De Octubre), Jacob Sands(Harvard University), Rebecca S. Heist(Massachusetts General Hospital), Byoung Chul Cho(Yonsei University), Dariusz M. Kowalski(The Maria Sklodowska-Curie National Research Institute of Oncology), Elaine Shum(NYU Langone’s Laura and Isaac Perlmutter Cancer Center), Wen Gu(Daiichi Sankyo (United States)), George R. Blumenschein(The University of Texas MD Anderson Cancer Center), Aaron Lisberg(APLA Health), Shunichi Sugawara(Sendai Kousei Hospital), Hong Zebger‐Gong(Daiichi Sankyo (Germany)), Enriqueta Felip(Institut Català d'Ornitologia), Wen‐Cheng Chang, Jong Seok Lee(Brigham and Women's Hospital), Lan Lan(Daiichi Sankyo (United States)), Elvire Pons‐Tostivint(Centre Hospitalier Universitaire de Nantes)
Cited by 49
Related Papers
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k